Buy & Sell J M Smucker Co (SJM) – J M Smucker Co Price Today
Aura AI Summary
Key Stats
- $11.99BMarket Cap
- Consumer StaplesSector
- -16.81%3M Drawdown
- $19.39BEnterprise Value
- 3.91%Dividend Yield
- 31% Buy | 69% SellTrading Activity
- 73 daysTypical Hold Time
J M Smucker Co (SJM) is currently valued at a market capitalization of $11.99B, with an enterprise value of $19.39B. Over the past 52 weeks, J M Smucker Co has traded between a low of $89.53 and a high of $116.64, highlighting its annual price range. Over the past three months, J M Smucker Co has recorded a drawdown of -16.81%, reflecting recent price volatility. J M Smucker Co offers a dividend yield of 3.91%, with the most recent dividend of $1.10 paid on 15 May 26. On average, investors hold J M Smucker Co for approximately 73 days, indicating typical investor behavior on the platform.
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Most Recent News
Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide
The Global Initiative on Loneliness and Connection (GILC) convened the 2026 Global Connection Forum on June 17 to address the growing public health crisis of loneliness and social isolation, which contribute to serious health risks and societal divis...
Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...
Over 30 pharma companies race to develop 35+ lupus nephritis drugs, advancing treatment options globally.
The lupus nephritis clinical trial landscape is rapidly expanding with more than 30 pharmaceutical companies developing over 35 drugs targeting this serious autoimmune kidney condition. Key players like Novartis, Simcere, and Regeneron are advancing ...